PHARMACOECONOMIC ASSESSMENT OF APIXABAN VERSUS STANDARD OF CARE FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS

被引：1
|
作者：
Pradelli, L. [1 ]
Calandriello, M. [2 ]
Di Virgilio, R. [3 ]
Bellone, M. [1 ]
Tubaro, M. [4 ]
机构：
[1] AdRes HE&OR, Turin, Italy
[2] Bristol Myers Squibb Srl, HE OR Unit, Rome, Italy
[3] Pfizer Pharmaceut Inc, Rome, Italy
[4] San Filippo Neri Hosp, Rome, Italy
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1427
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV83
引用
收藏
页码：A486 / A487
页数：2
相关论文
共 50 条
  • [1] Comparative pharmacoeconomic assessment of apixaban vs. standard of care for the prevention of stroke in Italian atrial fibrillation patients
    Pradelli, Lorenzo
    Calandriello, Mario
    Di Virgilio, Roberto
    Bellone, Marco
    Tubaro, Marco
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2014, 15 : 15 - 25
  • [2] A PHARMACOECONOMIC ANALYSIS OF THE USE OF APIXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN RUSSIAN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Ryazhenov, V. V.
    Gorokhova, S. G.
    Gorokhov, V
    VALUE IN HEALTH, 2018, 21 : S99 - S99
  • [3] BUDGET IMPACT ANALYSIS OF APIXABAN VERSUS OTHER NOACS FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
    Pradelli, L.
    Calandriello, M.
    Di Virgilio, R.
    Bellone, M.
    Tubaro, M.
    VALUE IN HEALTH, 2014, 17 (07) : A479 - A479
  • [4] COST EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS OTHER NOACS FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
    Pradelli, L.
    Calandriello, M.
    Di Virgilio, R.
    Bellone, M.
    Tubaro, M.
    VALUE IN HEALTH, 2014, 17 (07) : A487 - A487
  • [5] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Thitima Kongnakorn
    Tereza Lanitis
    Lievens Annemans
    Vincent Thijs
    Sophie Marbaix
    Clinical Drug Investigation, 2014, 34 : 709 - 721
  • [6] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Kongnakorn, Thitima
    Lanitis, Tereza
    Annemans, Lievens
    Thijs, Vincent
    Marbaix, Sophie
    CLINICAL DRUG INVESTIGATION, 2014, 34 (10) : 709 - 721
  • [7] Erratum to: Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Thitima Kongnakorn
    Tereza Lanitis
    Lieven Annemans
    Vincent Thijs
    Sophie Marbaix
    Clinical Drug Investigation, 2014, 34 : 753 - 753
  • [8] Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
    Stevanovic, Jelena
    Pompen, Marjolein
    Le, Hoa H.
    Rozenbaum, Mark H.
    Tieleman, Robert G.
    Postma, Maarten J.
    PLOS ONE, 2014, 9 (08):
  • [9] Non-valvular atrial fibrillation and stroke prevention
    Hankey, GJ
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 174 (05) : 234 - 239
  • [10] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
    Canal Fontcuberta, G.
    Escolar Albaladejo, G.
    Betegon Nicolas, L.
    de Salas-Cansado, M.
    Rubio-Rodriguez, D.
    Rubio-Terres, G.
    VALUE IN HEALTH, 2013, 16 (07) : A523 - A523
12345